Crossmark

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes

Crossref DOI link: https://doi.org/10.1136/bmjdrc-2020-001832

Published Online: 2020-11-19

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Mora, Pablo F

Sutton, David R

Gore, Ashwini

Baliga, Bantwal

Goldfaden, Rebecca F

Nikkel, Carla

Sink II, John

Adams-Huet, Beverley
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03495908 at ClinicalTrials.gov

Documents that mention this clinical trial

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
https://doi.org/10.1136/bmjdrc-2020-001832
Funding

Funding for this research was provided by:

Valeritas (N/A)
License Information

License valid from 2020-11-18

Document is current

Any future updates will be listed below